Header Logo

Connection

WILLIAM G WIERDA to Sirolimus

Back to Details
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Sirolimus.
WILLIAM G WIERDA
Connection Strength
0.050
Sirolimus
  1. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.